Carboplatin‐induced myelosuppression as related to body weight in dogs. (15th June 2020)

• Record Type: Journal Article
• Authors: Coffee, Calli; Roush, James K.; Higginbotham, Mary Lynn
• Is Part Of: Veterinary and comparative oncology. Volume 18:Number 4(2020:Dec.)
• Page Start: 804
• Page End: 810
• Publication Date: 2020-06-15
• Subjects: canine -- chemotherapy -- neutropenia -- platinum agent -- thrombocytopenia -- veterinary oncology; Veterinary oncology -- Periodicals; Neoplasms -- veterinary -- Periodicals; 636.0896994005
• DOI: 10.1111/vco.12622
• Languages: English
• ISSNs: 1476-5810

Abstract

Abstract: Smaller dogs are known to have an increased risk of chemotherapy‐induced myelosuppression for doxorubicin, mitoxantrone and melphalan. This retrospective study aimed to determine if dogs <15 kg and <10 kg experienced greater degrees of myelosuppression following treatment with carboplatin chemotherapy compared with dogs ≥15 kg. One hundred and one dogs treated with carboplatin for a variety of malignancies were retrospectively analysed. Eight dogs (61%) weighing <10 kg, three (38%) weighing 10 kg to <15 kg and 14 (17%) weighing ≥15 kg experienced a grade 3 or 4 neutropenia. Five dogs (38%) weighing <10 kg, two (25%) weighing 10 kg to <15 kg and 13 (16%) weighing ≥15 kg experienced a grade 3 or 4 thrombocytopenia. Dogs <10 kg were significantly more likely to develop a grade 3 or 4 neutropenia following carboplatin than dogs ≥10 kg (3.5 RR; 95% CI, 1.9‐6.3; P < .001). Dogs <15 kg were also significantly more likely to develop a grade 3 or 4 neutropenia than dogs ≥15 kg (3 RR; 95% CI, 1.6‐5.6; P = .004). Dogs <10 kg were significantly more likely to develop a grade 3 or 4 thrombocytopenia than those dogs ≥10 kg (2.5 RR; 95% CI, 1.1‐5.6; P = .006). Hospitalization was significantly more likely for dogs <10 kg vs ≥10 kg ( P = .014) as well as for dogs <15 kg vs ≥15 kg ( P = .039). This study demonstrates an increased risk of carboplatin‐induced myelosuppression in dogs <15 kg, and particularly those <10 kg. This information should be considered by clinicians when making decisions regarding the initial carboplatin dose for smaller canine patients, especially those <15 kg.